Education
About Us
Working with TipRanks
Follow Us
Immunitybio Inc (DE:26CA)
NASDAQ:26CA
Total Valuation
ImmunityBio has a market cap or net worth of €7.93B. The enterprise value is €9.70B.
Market Cap€7.93B
Enterprise Value€9.70B
Share Statistics
ImmunityBio has 1,028,111,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,028,111,500
Owned by Insiders66.44%
Owned by Institutions2.30%
Financial Efficiency
ImmunityBio’s return on equity (ROE) is 0.70 and return on invested capital (ROIC) is -56.95%.
Return on Equity (ROE)0.70
Return on Assets (ROA)-0.70
Return on Invested Capital (ROIC)-56.95%
Return on Capital Employed (ROCE)-0.58
Revenue Per Employee168.83K
Profits Per Employee0.00
Employee Count671
Asset Turnover0.23
Inventory Turnover0.83
Valuation Ratios
The current PE Ratio of ImmunityBio is ―. ImmunityBio’s PEG ratio is 0.15.
PE Ratio―
PS Ratio16.08
PB Ratio-3.65
Price to Fair Value-3.65
Price to FCF-5.90
Price to Operating Cash Flow-28.14
PEG Ratio0.15
Income Statement
In the last 12 months, ImmunityBio had revenue of 113.29M and earned -351.40M in profits. Earnings per share was -0.38.
Revenue113.29M
Gross Profit112.53M
Operating Income-256.03M
Pretax Income-351.61M
Net Income-351.40M
EBITDA-223.56M
Earnings Per Share (EPS)-0.38
Cash Flow
In the last 12 months, operating cash flow was -304.94M and capital expenditures -3.07M, giving a free cash flow of -308.01M billion.
Operating Cash Flow-304.94M
Free Cash Flow-308.01M
Free Cash Flow per Share-0.30
Dividends & Yields
ImmunityBio pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.20
52-Week Price Change178.30%
50-Day Moving Average5.00
200-Day Moving Average2.86
Relative Strength Index (RSI)57.06
Average Volume (3m)6.28K
Important Dates
ImmunityBio upcoming earnings date is May 7, 2026, TBA (Confirmed).
Last Earnings DateMar 3, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
ImmunityBio as a current ratio of 5.10, with Debt / Equity ratio of -175.77%
Current Ratio5.10
Quick Ratio5.08
Debt to Market Cap0.46
Net Debt to EBITDA-3.53
Interest Coverage Ratio-2.28
Taxes
In the past 12 months, ImmunityBio has paid -135.00K in taxes.
Income Tax-135.00K
Effective Tax Rate<0.01
Enterprise Valuation
ImmunityBio EV to EBITDA ratio is -11.68, with an EV/FCF ratio of -8.46.
EV to Sales23.05
EV to EBITDA-11.68
EV to Free Cash Flow-8.46
EV to Operating Cash Flow-8.56
Balance Sheet
ImmunityBio has €242.82M in cash and marketable securities with €878.12M in debt, giving a net cash position of -€635.30M billion.
Cash & Marketable Securities€242.82M
Total Debt€878.12M
Net Cash-€635.30M
Net Cash Per Share-€0.62
Tangible Book Value Per Share-€0.56
Margins
Gross margin is 92.44%, with operating margin of -226.00%, and net profit margin of -310.18%.
Gross Margin92.44%
Operating Margin-226.00%
Pretax Margin-310.37%
Net Profit Margin-310.18%
EBITDA Margin-197.34%
EBIT Margin-211.04%
Analyst Forecast
The average price target for ImmunityBio is €9.68, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target€9.68
Price Target Upside26.39% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast―